Skip to main content
SpringerLink
Log in

What price personal genome exploration?

  • News Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Companies offering direct-to-consumer genomic information face tough questions about who regulates them, where they fit in health care and how to value their services. What will it take to move them from niche services to a broader customer base? Jeffrey Fox reports.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: DTC genomics companies have to navigate a patchwork of regulations at the state level.

References

  1. Stefansson, H. et al. Nature 455, 232–236 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Burrill & Company and ChangeWave Research. Personalized Medicine and Wellness Survey <http://www.burrillandco.com/content/CWSurvey_61708.pdf> (2008).

    Google Scholar 

  3. Bodmer, W. & Bonilla, C. Nat. Genet. 40, 695–701 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Washington, DC

    Jeffrey L Fox

Authors
  1. Jeffrey L Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fox, J. What price personal genome exploration?. Nat Biotechnol 26, 1105–1108 (2008). https://doi.org/10.1038/nbt1008-1105

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1008-1105

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation